- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sanofi India reports net profit at Rs 136.3 crore in Q2
![Sanofi India reports net profit at Rs 136.3 crore in Q2 Sanofi India reports net profit at Rs 136.3 crore in Q2](https://medicaldialogues.in/h-upload/2020/04/18/750x450_127459-125760-sanofi.webp)
Mumbai: Drug firm Sanofi India on Tuesday reported a net profit of Rs 136.3 crore for the second quarter ended June 30, 2020.
The company had posted a net profit of Rs 97.4 crore for the corresponding period of the previous fiscal, Sanofi India said in a BSE filing.
Revenue from operations stood at Rs 710.5 crore for the quarter under consideration. It was Rs 747.9 crore for the same period year ago, it added.
"The financial results for the quarter ended June 30, 2020, are not comparable with that of the corresponding quarter in 2019 due to completion of slump sale transaction on May 29, 2020, which resulted in transfer of Ankleshwar manufacturing facility and few products to Zentiva Private Limited," Sanofi India said.
For the June quarter, the company has reported a drop in sales by 5 per cent. Some therapy areas were impacted negatively due to the COVID-19 restrictions, it added.
During the said quarter, the company was able to maintain operations at its manufacturing locations and warehouses to ensure uninterrupted supply of pharma products, Sanofi India said.
In a separate filing, the company said its board has approved the appointment of Rahul Bhatnagar as additional director (non-executive & independent) of the company from July 29, 2020. The board has also approved the appointment of Marc-Antoine Lucchini as additional director (non-executive) from the same date, it added.
Read also: Sanofi India Appoints Two New Directors Rahul Bhatnagar, Marc-Antoine Lucchini To Its Board
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751